(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual revenue growth rate of 29.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.6%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Verrica Pharmaceuticals's revenue in 2026 is $22,891,000.On average, 9 Wall Street analysts forecast VRCA's revenue for 2026 to be $427,391,017, with the lowest VRCA revenue forecast at $380,475,752, and the highest VRCA revenue forecast at $479,803,493. On average, 9 Wall Street analysts forecast VRCA's revenue for 2027 to be $687,168,619, with the lowest VRCA revenue forecast at $525,258,561, and the highest VRCA revenue forecast at $896,474,947.
In 2028, VRCA is forecast to generate $844,577,835 in revenue, with the lowest revenue forecast at $609,434,612 and the highest revenue forecast at $1,118,338,969.